ArticleOncoimmunology2026
Spatial transcriptomics unveils immune cellular ecosystems associated with patient survival in diffuse large B-cell lymphoma.
Article in Oncoimmunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diffuse large B-cell Lymphoma (DLBCL) is the most prevalent subtype of non-Hodgkin's lymphoma for which current therapeutic strategies remain insufficient, in part owing to heterogeneity in tumor biology and the immune microenvironment. The diffuse nature of DLBCL represents a challenge to elucidate how malignant and immune cells are spatially organized within the tumor microenvironment (TME), and how this organization impacts immune function and clinical outcome. Here, we performed a pilot spatial transcriptomics analysis of primary DLBCL tissue sections to resolve spatial gene expression patterns and cell-cell interactions, with key cellular features validated at the protein level. We identified six recurrent, spatially organized cellular ecosystems (Cell-Eco) defined by distinct immune compositions, transcriptional programs, and neighborhood architectures. Notably, ecosystems with similar immune cell abundance exhibited divergent functional states and opposite clinical associations, demonstrating that spatial context and local interactions, rather than cell-type frequency alone, shape immune function within the DLBCL TME. Building on these spatial ecosystems, we derived Cell-Eco gene signatures that generated prognostic scores and robustly stratified patient survival in large, independent DLBCL cohorts comprising more than 1000 cases. Across ecosystems, tumor-associated macrophages have emerged as the dominant spatial partners of malignant B cells, highlighting their central role in structuring the immune microenvironment. Together, these findings establish a spatially informed framework for DLBCL immune organization and demonstrate the prognostic relevance of tumor cellular architecture.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.